Mavacamten significantly reduces the long-term need for septal reduction therapy in severely symptomatic obstructive HCM patients.
At 128 weeks, 80.5% of patients experienced at least one class improvement in New York Heart Association (NYHA) functional status; nearly half had at least two-class improvement.
The treatment demonstrated sustained reduction in left ventricular outflow tract gradients with good overall tolerability.
Approximately 90% of patients remained on long-term mavacamten, indicating good adherence and manageable safety profile.
